TBPH
Theravance Biopharma Inc
$16.93
-0.05
(-0.29%)
Mkt Cap
877.45M
Volume
868,561
52W Range
10.822-21.03
Sector
Healthcare
Beta
0.17
EPS (TTM)
2.26
P/E Ratio
7.48
Revenue (TTM)
109.78M
Rev Growth (5Y)
+8.4%
EPS Growth (5Y)
N/A
AlphaVal · Fair Value
What we estimate one share is worth
$49.20
Undervalued
strong signal
65.6% below fair value
Modeled from cash flows & growth.
AlphaQuality · Grade · Gated
How strong & durable the business is
F
Platform & Compounding FCF
30.0 / 100 pillar composite (overridden)
A platform business that compounds free cash flow — graded A–F vs. similar companies.
Company Description
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 107.46M | 64.38M | 57.42M | 51.35M | 55.31M | 71.86M | 73.41M | 60.37M | 15.39M | 48.65M | 42.13M | 11.69M |
| Net Income | 105.89M | (56.42M) | (55.19M) | 872.13M | (199.43M) | (278.02M) | (236.46M) | (215.52M) | (285.40M) | (190.67M) | (182.22M) | (237.04M) |
| EPS | 2.10 | -1.15 | -1.00 | -1.26 | -2.87 | -4.46 | -4.25 | -3.99 | -5.45 | -4.26 | -5.34 | -7.46 |
| Free Cash Flow | 238.50M | (11.87M) | (29.48M) | (187.56M) | (211.26M) | (257.02M) | (241.37M) | (120.11M) | (203.46M) | (101.12M) | (171.50M) | (178.26M) |
| FCF / Share | 4.74 | -0.24 | -0.53 | -2.55 | -3.04 | -4.12 | -4.34 | -2.23 | -3.89 | -2.26 | -5.02 | -5.61 |
| Operating CF | 238.54M | (11.54M) | (27.00M) | (186.99M) | (207.86M) | (250.40M) | (238.20M) | (112.87M) | (201.05M) | (98.99M) | (168.86M) | (175.16M) |
| Total Assets | 485.57M | 354.16M | 382.00M | 607.40M | 374.82M | 469.06M | 408.83M | 560.24M | 441.40M | 639.25M | 300.12M | 337.77M |
| Total Debt | 75.50M | 49.82M | 49.16M | 52.16M | 669.52M | 676.26M | 510.53M | 454.35M | 223.75M | 222.68M | 0 | 0 |
| Cash & Equiv | 167.81M | 37.80M | 39.55M | 298.17M | 89.96M | 81.47M | 58.06M | 378.02M | 88.98M | 344.71M | 112.71M | 89.22M |
| Book Value | 296.72M | 175.54M | 213.00M | 441.80M | (338.57M) | (303.75M) | (223.84M) | (51.59M) | 115.18M | 350.23M | 243.06M | 289.79M |
| Return on Equity | 0.36 | -0.32 | -0.26 | 1.97 | N/A | N/A | N/A | N/A | -2.48 | -0.54 | -0.75 | -0.82 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17.70M | 45.89M | 19.99M | 26.20M | 15.39M | 18.75M | 16.87M | 14.26M | 14.50M | 17.57M | 15.69M | 13.75M |
| Net Income | (4.93M) | 61.02M | 3.62M | 54.84M | (13.58M) | (15.53M) | (12.70M) | (16.53M) | (11.66M) | (8.51M) | (8.95M) | (15.64M) |
| EPS | -0.10 | 1.20 | 0.07 | 1.09 | -0.27 | -0.31 | -0.26 | -0.34 | -0.24 | -0.17 | -0.17 | -0.28 |
| Free Cash Flow | 73.28M | (6.07M) | (6.51M) | 208.04M | 43.04M | (1.09M) | (5.21M) | (4.45M) | (1.11M) | (1.53M) | (2.51M) | (13.29M) |
| FCF / Share | 1.43 | -0.12 | -0.13 | 4.15 | 0.87 | -0.02 | -0.11 | -0.09 | -0.02 | -0.03 | -0.05 | -0.23 |
| Operating CF | 73.28M | (6.06M) | (6.51M) | 208.07M | 43.04M | (902,000) | (5.20M) | (4.42M) | (1.02M) | (854,000) | (2.49M) | (12.44M) |
| Total Assets | 472.31M | 485.57M | 415.46M | 426.04M | 343.58M | 354.16M | 356.11M | 362.03M | 371.31M | 382.00M | 413.59M | 446.63M |
| Total Debt | 73.30M | 75.50M | 44.59M | 46.46M | 48.16M | 49.82M | 44.98M | 46.66M | 47.90M | 49.16M | 50.83M | 51.68M |
| Cash & Equiv | 288.10M | 167.81M | 174.77M | 281.93M | 110.61M | 37.80M | 23.38M | 46.34M | 53.84M | 39.55M | 71.69M | 105.60M |
| Book Value | 290.59M | 296.72M | 232.68M | 224.85M | 165.98M | 175.54M | 185.65M | 193.69M | 204.87M | 213.00M | 246.13M | 280.16M |
| Return on Equity | -0.02 | 0.21 | 0.02 | 0.24 | -0.08 | -0.09 | -0.07 | -0.09 | -0.06 | -0.04 | -0.04 | -0.06 |
TBPH News
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--TBPH, IRDM, LCII, and PATK
Here's Why Zymeworks Inc. Paid $929M For Theravance Biopharma
Theravance Stock Down 3% After Zymeworks Announces Buyout
Are IRDM, TBPH, SYNA, TECH Obtaining Fair Deals for their Shareholders?
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Theravance Biopharma, Inc. (NASDAQ: TBPH)
Are IRDM, TBPH, SYNA, TECH Obtaining Fair Deals for their Shareholders?
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Theravance Biopharma, Inc. (NASDAQ: TBPH)
TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders
Shareholder Alert: Ademi LLP investigates whether Theravance Biopharma, Inc. is obtaining a Fair Price for Public Shareholders
Shareholder Alert: Ademi LLP investigates whether Theravance Biopharma, Inc. is obtaining a Fair Price for Public Shareholders